WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017181004) SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2017/181004    International Application No.:    PCT/US2017/027618
Publication Date: 19.10.2017 International Filing Date: 14.04.2017
IPC:
C07D 333/70 (2006.01), C07D 339/06 (2006.01), C07D 401/12 (2006.01), C07D 235/24 (2006.01), C07D 405/12 (2006.01), C07D 409/12 (2006.01), C07D 471/04 (2006.01), C07D 209/42 (2006.01), C07D 295/192 (2006.01), C07D 307/85 (2006.01), A61P 25/16 (2006.01), A61P 25/28 (2006.01), A61P 25/14 (2006.01)
Applicants: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; National Institutes of Health Office of Technology Transfer 6011 Executive Boulevard Suite 325, MSC 7660 Bethesda, Maryland 20892-7660 (US).
UNIVERSITY OF KANSAS [US/US]; 245 Strong Hall 1450 Jayhawk Boulevard Lawrence, Kansas 66045 (US)
Inventors: SIBLEY, David R.; (US).
MORITZ, Amy Elizabeth; (US).
FREE, R. Benjamin; (US).
STEINER, Joseph P.; (US).
SOUTHALL, Noel Terrence; (US).
FERRER, Marc; (US).
HU, Xin; (US).
WEINER, Warren S.; (US).
AUBÉ, Jeffrey; (US).
FRANKOWSKI, Kevin; (US)
Agent: MAXWELL, Leslie-Anne; (US)
Priority Data:
62/322,361 14.04.2016 US
Title (EN) SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE
(FR) AGONISTES SÉLECTIFS DU RÉCEPTEUR DE LA DOPAMINE D3 ET LEURS PROCÉDÉS D'UTILISATION
Abstract: front page image
(EN)The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula (I) is administered to the patient together with one or more additional active agents.
(FR)L'invention concerne un composé de formule (I) ou un sel pharmaceutiquement acceptable de celui-ci (I), les variables W, R1, R2, R3 et R4 étant définies dans la description. L'invention concerne un composé ou un sel de formule (I) ainsi qu'un support pharmaceutiquement acceptable. L'invention concerne également des procédés de traitement d'un patient pour la maladie de Parkinson et les syndromes associés, la dyskinésie, notamment les dyskinésies secondaires au traitement de la maladie de Parkinson par L-DOPA, des troubles neurodégénératifs tels que la maladie d'Alzheimer et la démence, la maladie de Huntington, le syndrome des jambes sans repos, le trouble bipolaire et la dépression, la schizophrénie, le dysfonctionnement cognitif ou les troubles de l'utilisation de la substance, les procédés consistant à administrer un composé de formule I ou un sel de celui-ci au patient. L'invention concerne des méthodes de traitement combinées dans lesquelles le composé de formule (I) est administré au patient conjointement avec un ou plusieurs agents actifs supplémentaires.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)